美国食品药品监督管理局批准一种无细胞百日咳疫苗用于白喉、破伤风和百日咳疫苗接种系列的前四剂。 - Suppr | 超能文献

Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series.

出版信息

MMWR Morb Mortal Wkly Rep. 1996 Aug 9;45(31):676-7.

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series.美国食品药品监督管理局批准一种无细胞百日咳疫苗用于白喉、破伤风和百日咳疫苗接种系列的前四剂。

MMWR Morb Mortal Wkly Rep. 1996 Aug 9;45(31):676-7.

2

FDA approval of a fourth acellular pertussis vaccine for use among infants and young children.美国食品药品监督管理局批准第四种无细胞百日咳疫苗用于婴幼儿。

MMWR Morb Mortal Wkly Rep. 1998 Nov 6;47(43):934-6.

3

FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine.美国食品药品监督管理局批准一种通过与无细胞百日咳疫苗复溶组合而成的b型流感嗜血杆菌结合疫苗。

MMWR Morb Mortal Wkly Rep. 1996 Nov 15;45(45):993-5.

4

FDA approval of a second acellular pertussis vaccine for use among infants and young children.

MMWR Morb Mortal Wkly Rep. 1997 Feb 7;46(5):110-1.

5

Food and Drug Administration approval of use of diphtheria and tetanus toxoids and acellular pertussis vaccine.美国食品药品监督管理局批准使用白喉和破伤风类毒素及无细胞百日咳疫苗。

MMWR Morb Mortal Wkly Rep. 1991 Dec 20;40(50):881-2.

6

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.美国食品药品监督管理局批准扩大破伤风类毒素、低剂量白喉类毒素和无细胞百日咳疫苗的适用年龄范围。

MMWR Morb Mortal Wkly Rep. 2009 Apr 17;58(14):374-5.

7

Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children--United States, 2002.

MMWR Morb Mortal Wkly Rep. 2002 Jul 5;51(26):574.

8

Food and Drug Administration approval of a second diphtheria and tetanus toxoids and acellular pertussis vaccine.美国食品药品监督管理局批准第二种白喉、破伤风类毒素和无细胞百日咳疫苗。

MMWR Morb Mortal Wkly Rep. 1992 Aug 28;41(34):630-1.

9

Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.对2岁以下儿童同时接种甲型肝炎灭活疫苗与白喉-破伤风-无细胞百日咳疫苗和B型流感嗜血杆菌疫苗的免疫原性和安全性。

Pediatrics. 2006 Sep;118(3):e602-9. doi: 10.1542/peds.2005-2755.

10

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.FDA 批准破伤风类毒素、白喉类毒素和无细胞百日咳疫苗的使用年龄扩大。

MMWR Morb Mortal Wkly Rep. 2011 Sep 23;60(37):1279-80.

引用本文的文献

1

A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States.疫苗效力和保护持续时间的变化解释了美国近期百日咳发病率上升的原因。

PLoS Comput Biol. 2015 Apr 23;11(4):e1004138. doi: 10.1371/journal.pcbi.1004138. eCollection 2015 Apr.

2

Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells.一种重组的、全长的、无毒破伤风神经毒素进入Neuro-2a细胞。

Infect Immun. 2014 Feb;82(2):873-81. doi: 10.1128/IAI.01539-13. Epub 2013 Dec 9.

3

Evaluation for tetanus antibodies in Korean-Americans living in the New York area: a pilot study.

J Immigr Minor Health. 2009 Apr;11(2):105-7. doi: 10.1007/s10903-008-9123-9. Epub 2008 Mar 18.

4

An overview of the status of acellular pertussis vaccines in practice.

Drugs. 1997 Aug;54(2):189-96. doi: 10.2165/00003495-199754020-00001.